EXOGENOUS GLUCAGON-LIKE PEPTIDE-1 ATTENUATES THE GLYCAEMIC RESPONSE TO ENTERAL NUTRIENT IN CRITICALLY ILL PATIENTS WITH PRE-EXISTING TYPE-2 DIABETES MELLITUS

被引：0
|
作者：
Deane, A. [1 ,2 ]
Chapman, M. J. [1 ,2 ]
Fraser, R. J. [3 ]
Summers, M. J. [4 ]
Zaknic, A. V. [4 ]
DiBartolomeo, A. [2 ]
Horowitz, M. [3 ]
机构：
[1] Royal Adelaide Hosp, Intens Care Unit, Adelaide, SA 5000, Australia
[2] Univ Adelaide, Discipline Acute Care Med, Adelaide, SA, Australia
[3] Univ Adelaide, Discipline Med, Adelaide, SA, Australia
[4] Royal Adelaide Hosp, Dept Gastroenterol, Adelaide, SA 5000, Australia
来源：
INTENSIVE CARE MEDICINE | 2010年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
0346
引用
收藏
页码：S172 / S172
页数：1
相关论文
共 50 条
  • [21] Effectiveness of glucagon-like peptide-1 agonists in type 2 diabetes
    Pavlicek, Vojtech
    DIABETOLOGIE, 2023, 19 (03): : 359 - 360
  • [22] Advantages of glucagon-like peptide-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus: A review
    Demidova, Tatiana Yu.
    Titova, Victoria V.
    Izmaylova, Maryam Ya.
    TERAPEVTICHESKII ARKHIV, 2023, 95 (10) : 876 - 880
  • [23] Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
    Gutzwiller, JP
    Drewe, J
    Göke, B
    Schmidt, H
    Rohrer, B
    Lareida, J
    Beglinger, C
    AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1999, 276 (05) : R1541 - R1544
  • [24] Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
    Toft-Nielsen, MB
    Madsbad, S
    Holst, JJ
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (08): : 3853 - 3860
  • [25] Therapeutics Glucagon-like peptide-1 analogues for type 2 diabetes
    Wilding, John P. H.
    Hardy, Kevin
    BRITISH MEDICAL JOURNAL, 2011, 342 : 433 - 435
  • [26] Glucagon-like peptide-1 in type 2 diabetes:: the β-cell and beyond
    Nauck, Michael A.
    DIABETES OBESITY & METABOLISM, 2008, 10 : 2 - 13
  • [27] Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes
    Edwards, C. M. B.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2013, 74 (04) : 198 - 201
  • [28] Impaired postprandial release of glucagon-like peptide-1 in patients with Type 2 diabetes
    Lindqvist, J
    Pigon, J
    Holst, JJ
    Efendic, S
    DIABETOLOGIA, 1998, 41 : A184 - A184
  • [29] Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes
    De Block, Christophe E. M.
    Dirinck, Eveline
    Verhaegen, Ann
    Van Gaal, Luc F.
    DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 788 - 805
  • [30] Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: Relationship to glycemia
    Deane, Adam M.
    Chapman, Marianne J.
    Fraser, Robert J. L.
    Summers, Matthew J.
    Zaknic, Antony V.
    Storey, James P.
    Jones, Karen L.
    Rayner, Christopher K.
    Horowitz, Michael
    CRITICAL CARE MEDICINE, 2010, 38 (05) : 1261 - 1269
12345